Abstract: The present invention relates to a stable pharmaceutical composition comprising a fixed dose combination of a therapeutically effective amount of DPP-IV inhibitor and a therapeutically effective amount of SGLT2 inhibitor for reducing blood glucose level in patients with diabetes. The present invention specifically relates to a stable pharmaceutical composition comprising Sitagliptin or a pharmaceutically acceptable salts or solvate or hydrate or premix thereof and Empagliflozin or a pharmaceutically acceptable salt or solvate or hydrate or premix thereof in the presence of one or more pharmaceutically acceptable excipients. Moreover, the present invention relates to a stable pharmaceutical composition comprising Sitagliptin Phosphate Monohydrate, Empagliflozin and one or more pharmaceutically acceptable excipients with high content uniformity, reduced degradation impurities and optimum dissolution.

Abstract: The present invention relates to an orally disintegrating pharmaceutical dosage forms of apixaban or a pharmaceutically acceptable salt or prodrug thereof. The present invention specifically relates to a stable orally disintegrating pharmaceutical composition comprising apixaban and one or more pharmaceutically acceptable excipients. Further, the present invention relates to an orally disintegrating dosage form comprising apixaban, at least one disintegrating excipient and optionally one or more pharmaceutically acceptable excipients for treatment of disorders associated with Factor Xa.